| 일 | 월 | 화 | 수 | 목 | 금 | 토 |
|---|---|---|---|---|---|---|
| 1 | 2 | |||||
| 3 | 4 | 5 | 6 | 7 | 8 | 9 |
| 10 | 11 | 12 | 13 | 14 | 15 | 16 |
| 17 | 18 | 19 | 20 | 21 | 22 | 23 |
| 24 | 25 | 26 | 27 | 28 | 29 | 30 |
- Investment
- China Construction Bank
- capital gate
- Malaysia
- Korea M&A
- Bank
- cgi korea
- M&A
- China
- Confidential Agreement
- Merger
- OTCBB
- PEF
- Japan
- case study
- Japan Tobacco
- Korea
- securities
- acquisition
- CA
- LOTTE
- Acquistion
- buyout
- Letter of intent
- hong kong
- nda
- sk
- private equity
- LOI
- taiwan
- Today
- Total
Korea M&A Corporation
GlaxoSmithKline (GSK) and OncoMed Pharmaceuticals (OncoMed) today announced a worldwide strategic alliance to discover, develop and market novel antibody therapeutics to target cancer stem cells which are believed to play a key role in the establishment, metastasis and recurrence of cancer. The alliance with GSK will be conducted through its Center of Excellencefor External Drug Discovery (CEEDD..
Eisai said this morning that it’s dropping $3.9 billion in cash to pick up MGI Pharma, a Minnesota-based company that sells cancer drugs. Consider the deal a parachute for the company to wear when it falls off the patent cliff in 2010, as its biggest selling drug, the Alzheimer’s medicine Aricept, loses patent protection. The Japanese drug business has been struggling — prompting the nation’s he..